Trevi Therapeutics (TRVI) Other Non Operating Income (2021 - 2025)
Trevi Therapeutics' (TRVI) quarterly Other Non Operating Income came in at $30000.0 in Q4 2025, down 96.71% year-on-year from $912000.0 in Q4 2024, and up 1600.0% quarter-over-quarter from -$2000.0 in Q3 2025.
Trevi Therapeutics (TRVI) Other Non Operating Income (2021 - 2025) Analysis & Trends
Trevi Therapeutics' Other Non Operating Income history runs 5 years deep, the most recent figure standing at $30000.0 for Q4 2025.
- On a quarterly basis, Other Non Operating Income fell 96.71% year-over-year to $30000.0 in Q4 2025; TTM through Dec 2025 was $933000.0, a 4.25% increase from a year earlier, with the FY2025 full-year figure at $14000.0, down 98.44% from the prior year.
- Other Non Operating Income improved to $30000.0 in Q4 2025 per TRVI's latest filing, from -$2000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $5.5 million in Q4 2022 and bottomed at -$404000.0 in Q4 2021.
- The 5-year median for Other Non Operating Income is -$2500.0 (2023), against an average of $356111.1.
- Across the five-year window, Other Non Operating Income sank 440.0% in 2022 and jumped 30500.0% in 2024, its largest moves.
- Year by year, Other Non Operating Income stood at -$404000.0 in 2021, then jumped by 1473.02% to $5.5 million in 2022, then sank by 100.05% to -$3000.0 in 2023, then soared by 30500.0% to $912000.0 in 2024, then sank by 96.71% to $30000.0 in 2025.
- Per Business Quant, the three latest TRVI Other Non Operating Income figures stand at $30000.0 (Q4 2025), -$2000.0 (Q3 2025), and -$7000.0 (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Trevi Therapeutics | 2.54 Bn | 2.54 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 30,000.00 |
| Sep 30, 2025 | -2,000.00 |
| Jun 30, 2025 | -7,000.00 |
| Dec 31, 2024 | 912,000.00 |
| Sep 30, 2024 | -11,000.00 |
| Jun 30, 2024 | -5,000.00 |
| Mar 31, 2024 | -1,000.00 |
| Dec 31, 2023 | -3,000.00 |
| Sep 30, 2023 | 154,000.00 |
| Jun 30, 2023 | 153,000.00 |
| Mar 31, 2023 | 165,000.00 |
| Dec 31, 2022 | 5.55 Mn |
| Jun 30, 2022 | -136,000.00 |
| Mar 31, 2022 | -11,000.00 |
| Dec 31, 2021 | -404,000.00 |
| Sep 30, 2021 | -5,000.00 |
| Jun 30, 2021 | 40,000.00 |
| Mar 31, 2021 | -6,000.00 |